Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 210, 107486
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancerCancer Immunology, Immunotherapy, 2024
- Expanding Biology of PCSK9: Roles in Atherosclerosis and BeyondCurrent Atherosclerosis Reports, 2022
- Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary CholangitisInflammation, 2022
- Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor PathwaysClinical Reviews in Allergy & Immunology, 2020
- Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastomaApplied Microbiology and Biotechnology, 2018
- Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studiesAtherosclerosis, 2018
- Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytesBiomedicine & Pharmacotherapy, 2016
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic ChallengesCurrent Atherosclerosis Reports, 2011
- Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivoAtherosclerosis, 2006
- Lipids, risk factors and ischaemic heart diseaseAtherosclerosis, 1996